KromaTiD, Inc., a Longmont, Colorado-based maker of a directional Genomic Hybridization (dGHTM) platform, completed its Series A financing round.
First Capital Ventures made the investment, whose amount was not disclosed.
The company intends to use the funds to advance the development of its platform, contributing to capability and capacity expansion, including further optimization of critical artificial intelligence-based image analysis capabilities.
Led by CEO Christopher Tompkins, PhD, KromaTiD is advancing a directional Genomic Hybridization (dGHTM) platform providing tools for understanding the success and quality of edits at the cellular level. Its products and services are already used by top gene editing companies to get their advanced therapies to market.
The company focuses on enabling CRISPR and other gene editing technologies.